ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2633

Clinical Spectrum Of Cutaneous Vasculitis

Javier Loricera1, Vanesa Calvo-Río1, Francisco Ortiz-Sanjuan2, Héctor Fernández-Llaca3, Marcos A. González-López4, Lino Álvarez5, M. Carmen González-Vela6, Domingo González-Lamuño7, Cristina Mata2, Javier Rueda-Gotor8, Víctor M. Martínez-Taboada9, Miguel Angel González-Gay2 and Ricardo Blanco10, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 2Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 3Dermatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 4Dermatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 5Pediatrics, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 6Pathology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 7Pediatrics, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander, Santander, Spain, 8Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, 9Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV., Santander, Spain, 10Hospital Marques de Valdecilla, Santander, Spain

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Cutaneous vasculitis (CV) encompasses a large and heterogeneous set of syndromes characterized by inflammation of the skin vessels. The most common clinical manifestation is palpable purpura with leukocytoclastic vasculitis in biopsy. Our objective was to study clinical associations of a large series of patients with CV.

Methods:

Study of 817 consecutive and unselected patients with CV of the same university hospital. The diagnosis required histological confirmation except in obvious cases like Henoch-Schönlein Purpura (HSP) in childhood.Primary vasculitic syndromes were classified according to the classification of Chapel Hill (Jennette J et al. Arthritis Rheum 1994; 37:187).Secondary vasculitis were considered those due to malignancies, major infections and connective tissue diseases.The different clinical associations were studied according to different age groups, considering adults patients older than 20 years (Michel et al. J Rheumatol 1992; 19:721-8).

Results:

Of 817 patients (457 men/360 women), 459 were adults (mean age±SD, 55.3±17.5 years) and 358 childrenyoung (mean age ± SD, 7.5 ± 4.2 years).Of the 358 children-young, 355 had primary VC: HSP (279 cases), cutaneous leukocytoclastic angiitis (CLA) (68) and urticarial vasculitis (8).Of the 459 adults, 369 had a primary CV: CLA (239), HSP(105), urticarial vasculitis (12) and mixed cryoglobulinemia (13 patients).The CV was a manifestation of a systemic necrotizing vasculitis in 13 adults; polyarteritis nodosa (3), microscopic polyangiitis (4), Wegener’s disease (3) and Churg-Strauss syndrome (3).In addition, the CV was secondary to other processes in 77 adults: connective tissue diseases (34), severe infection (25), neoplasia (18).There were only three children-young patients, who had a secondary CV, a major infection (2 cases) and a connective tissue disease (1 case).Patients in which the CV was secondary to systemic necrotizing vasculitis, connective, serious infections or malignancies had clinical and laboratory data suggestive of this underlying disease.

Conclusion:

CV in children in most cases (99.2%) is primary, usually HSP or CLA, and has a good prognosis.By contrast, in adults a 22.4% is due to malignancies, major infections, connective tissue diseases, systemic necrotizing vasculitis or cryoglobulinemic vasculitis. Therefore, clinical assotiations depends of age, being more serious in adults.


Disclosure:

J. Loricera,
None;

V. Calvo-Río,
None;

F. Ortiz-Sanjuan,
None;

H. Fernández-Llaca,
None;

M. A. González-López,
None;

L. Álvarez,
None;

M. C. González-Vela,
None;

D. González-Lamuño,
None;

C. Mata,
None;

J. Rueda-Gotor,
None;

V. M. Martínez-Taboada,
None;

M. A. González-Gay,
None;

R. Blanco,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-spectrum-of-cutaneous-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology